In the BioHarmony Drug Report Database
Talazoparib
Talzenna (talazoparib) is a small molecule pharmaceutical. Talazoparib was first approved as Talzenna on 2018-10-16. It is used to treat breast neoplasms in the USA. It has been approved in Europe to treat breast neoplasms. The pharmaceutical is active against poly [ADP-ribose] polymerase 2 and poly [ADP-ribose] polymerase 1. Talzenna’s patents are valid until 2031-10-20 (FDA).
Trade Name
|
Talzenna |
|---|---|
Common Name
|
talazoparib |
ChEMBL ID
|
CHEMBL3137320 |
Indication
|
breast neoplasms |
Drug Class
|
Poly-ADP-ribose polymerase inhibitors |
Image (chem structure or protein)